We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biofortuna Raises £1.6 Million in Funding Round
News

Biofortuna Raises £1.6 Million in Funding Round

Biofortuna Raises £1.6 Million in Funding Round
News

Biofortuna Raises £1.6 Million in Funding Round

Image Credit: Biofortuna
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biofortuna Raises £1.6 Million in Funding Round "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biofortuna has raised £1.6M in its latest funding round. The new funding supported by current investor Foresight VCTs and members of the senior management team will allow the company to take its ReadyPlex™ rapid blood group genotyping assays into clinical trials and commercialisation, as well as invest in additional resources in its contract manufacturing infrastructure.

The ReadyPlex product family is an exciting new range of real-time PCR based products for genomic analysis of blood groups, platelet antigens, neutrophil antigens and coagulation polymorphisms. In addition to launching this new product range, Biofortuna will also be investing in its freeze drying production, dispensing and packaging capabilities, to match the growth of its successful contract development and manufacturing service.

Simon Douglas, CEO of Biofortuna, stated: “I am delighted that the new investment will be used to bring to market the ReadyPlex product range and expand our lyophilisation infrastructure to meet current and future demand for our IVD contract services.”

This article has been republished from materials provided by Biofortuna. Note: material may have been edited for length and content. For further information, please contact the cited source.






Advertisement